

AI-driven Discovery and Profiling of GTAEXS-617, a Selective and Highly Potent Inhibitor of CDK7


J  r  my Besnard¹, James Joseph², Haiyun Bai², Ross Paveley¹, Tao Wang², Olivier Barbeau¹, Xiao-Hui Gu², Andrew Bell¹, Mate Somlyay¹, Christina Taubert¹, Christophe Boudesco¹, Gregory Vladimer¹, Fred Aswad² ¹Exscientia, ²GT Apeiron



Poster #3930


Booth: 2016

INTRODUCTION



Cyclin-dependent kinase 7 (CDK7) is an attractive therapeutic target in oncology, due to its dual role in regulating cell cycle progression and transcription, both dysregulated during tumourigenesis. Inhibiting CDK7 has been shown to severely limit the pro-liferative capacity of cancer cells *in vitro* and *in vivo*; however, developing effective CDK7 inhibitors (CDK7i) has proven challenging due to selectivity and tolerability issues, including GI tract toxicity.

METHODS



- Our AI platform and knowledge transfer from large kinase datasets were leveraged to identify starting points.
- Key objectives were to improve tolerability and reduce the side effects of CDK7i.
- *In vivo* PK data and *in vitro* endpoints from Caco-2 permeability were incorporated into multi-parameter optimisation to exploit active learning methods.
- Active learning algorithms provided an efficient search of chemical space to drive design towards potent and permeable compounds.
- Ranking of compounds to move into efficacy assays was performed via an automated pipeline for early human dose prediction.

RESULTS

Figure 1: Rapid discovery of GTAEXS-617, a potent and permeable CDK7i




Figure 1: (A) Key GTAEXS-617 potency and ADMET profile features. (B) Anti-proliferative effects of GTAEXS-617 measured at 3 days on ovarian, TNBC and normal cell lines (OVCAR3 measured at 5 days).

Figure 2: Highly selective across whole kinome




Figure 2: GTAEXS-617 fold selectivity against (A) other CDK family members (Km ATP), *pKD measured by SPR, (B) off-target activity against whole kinome run at 3   M in kinase profiler assay at Eurofins. (C) Cell based kinase selectivity was assessed in ActivX KiNativ platform at 3   M.

Figure 3: Tumour regression activity and tolerability observed in xenograft models




Figure 3: Efficacy of GTAEXS-617 at low doses in both ovarian and TNBC xenograft models (A) OVCAR3 and (B) HCC70.

(C-D) GTAEXS-617 is well tolerated at efficacious doses in both models with no effect on body weight change.

Figure 4: AI platform leveraged to test ovarian cancer samples, revealing insight into heterogeneity in patient response




Figure 4: (A) DMSO normalised cancer cell numbers at baseline or treatment with increasing concentrations of GTAEXS-617 in N=10 primary ovarian cancer samples. (B) Cancer cell fractions at baseline and over concentration of *ex vivo* treatment of GTAEXS-617; subjective grouping of patient sample responses correlating to dose response curves in (A). Boxplots and outliers shown. (C) DMSO normalised relative cell number of immune cells (black) or cancer cells (blue) after treatment with increasing concentrations of GTAEXS-617 and the CDK4/6 inhibitor palbociclib; boxplots of N=10.

CONCLUSIONS

- Our AI-driven platform enabled rapid and efficient discovery of an orally bioavailable, selective small-molecule antagonist of CDK7 with high on-target potency: GTAEXS-617.
- Design criteria were met after synthesising only 136 compounds.
- Limitations traditionally associated with CDK7i were overcome during the design process, including high efflux.
- Potent anti-tumour activity of GTAEXS-617 was shown *in vivo*.
- In primary ovarian cancer samples, two response groups appear to be forming following CDK7 inhibition, distinguished by dose response curves starting early versus a plateau effect.
- GTAEXS-617 tended to demonstrate less immune cell toxicity compared to a clinical CDK4/6 inhibitor.
- Researchers aim to leverage these insights to elucidate a patient selection or PD biomarker.
- These data support the advancement of our AI-designed CDK7i GTAEXS-617 towards clinical development.

AI-driven discovery of our CDK7i was rapid, efficient and provided early insights into patient response.

For more information: contact@exscientia.ai

